Merck & Co. has confirmed its $10 billion acquisition of London-based Verona Pharma, a significant move aimed at enhancing its offerings in respiratory care. This acquisition includes access to Ohtuvayre® (ensifentrine), a first-in-class maintenance treatment for Chronic Obstructive Pulmonary Disease (COPD) in adults. The deal is expected to drive growth for Merck and diversify its portfolio beyond its blockbuster drug, Keytruda. Following the announcement, shares of Verona Pharma surged by 20%, reflecting strong market interest in the acquisition.